Pfenex to Announce First Quarter 2020 Financial Results on May 7
25 April 2020 - 6:05AM
Pfenex Inc. (NYSE American: PFNX) announced today that it will
report its financial results for the first quarter ended March 31,
2020, after the market close on Thursday, May 7, 2020. Pfenex will
host a conference call and webcast to discuss its financial results
and provide a company update that day at 1:30 PM Pacific Time (4:30
PM Eastern Time).
Conference Call & Webcast |
Thursday, May 7th @ 1:30 PM Pacific Time
(4:30 PM Eastern Time) |
Domestic: |
|
888-220-8451 |
International: |
|
856-344-9221 |
Conference ID: |
|
3922891 |
Webcast: |
|
http://public.viavid.com/index.php?id=139459 |
|
|
|
Webcast replays available through May 14th: |
Webcast: |
|
http://public.viavid.com/index.php?id=139459 |
|
|
|
About Pfenex Inc.
Pfenex is a development and licensing biotechnology company
focused on leveraging its Pfenex Expression Technology® to develop
and improve protein therapies for unmet patient needs. Using the
patented Pfenex Expression Technology platform, Pfenex has created
an advanced pipeline of potential therapeutic equivalents and novel
and next generation therapeutics. Pfenex’s lead product candidate
is PF708, a therapeutic equivalent candidate to Forteo®
(teriparatide injection). PF708 has been approved in the U.S. for
the treatment of osteoporosis in certain patients at high risk for
fracture, and marketing authorization applications are pending in
other jurisdictions. In addition, Pfenex is developing hematologic
oncology products in collaboration with Jazz Pharmaceuticals,
including PF743, a recombinant crisantaspase, and PF745, a
recombinant crisantaspase with half-life extension technology.
Pfenex also uses its Pfenex Expression Technology platform to
produce CRM197, a diphtheria toxoid carrier protein used in
prophylactic and therapeutic vaccines.
Pfenex investors and others should note that Pfenex announces
material information to the public about Pfenex through a variety
of means, including its website (http://www.pfenex.com/), its
investor relations website (http://pfenex.investorroom.com/), press
releases, SEC filings, public conference calls, corporate Twitter
account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Company Contact:
investorrelations@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Apr 2024 to May 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Pfenex Inc (American Stock Exchange): 0 recent articles
More News Articles